Final Height in Turner Syndrome Patients Treated with Growth Hormone

Abstract

The first treatment trials on patients presenting with Turner syndrome were successful in accelerating growth velocity. It is therefore essential to know the final height of the patients who were treated in order to ascertain whether or not growth hormone treatment increases final height. We are reporting on a group of 117 patients with Turner syndrome whose growth hormone treatment was initiated in 1986. The mean growth hormone dose was 0.74 IU/ kg/week for an average period of 4 years. At the start of treatment, the patients’ chronological age was 12⁹/₁₂ years, height -3.8 ± 1.0 standard deviation scores (SDS) and bone age 10.5 ± 2.1 years. Mean final height was 147.7 ± 5.6 cm, i.e. a gain of 1.5 SDS. We noted no significant difference due to the type of chromosomal abnormality, nor to oxandrolone or estrogen-associated treatment. A significant correlation was found between final height, mean parental height, the duration of the treatment, height SDS at the start of treatment and growth hormone peak during pharmacological stimulation tests. However, there was no correlation between growth hormone dosage, chronological age and bone age at the start of treatment. These results show that the growth hormone treatment improves the final heights of patients with Turner syndrome.

45,X/46,XX mosaicism below 30% of aneuploidy: clinical implications in adult women from a reproductive medicine unit

“…Thereby, mean height of TS patients in France is 142 cm (14), whereas mean normal height is 163 cm (15). It is known that TS patients with mosaicism are often taller than 45,X monosomic patients (16), but are also shorter than normal women.…”

Cardiovascular anomalies in children and young adults with Ullrich-Turner syndrome-the erlangen experience

“…[1][2][3] In recent years, most medical attention has been focused on the improvement of final height by recombinant human growth hormone therapy. [4][5][6][7] Another important therapeutic goal is substitution with estrogens in order to induce and maintain normal sexual development and to achieve optimal skeletal maturation. Thus, health surveillance in children with UTS was primarily conducted by pediatric endocrinologists.…”

Estatura final (EF) em síndrome de Turner (ST): experiência de 76 casos acompanhados na Unidade de Endocrinologia Pediátrica do Hospital de Clínicas da Universidade Federal do Paraná

“…A explicação para esse achado não é clara, embora se possa aventar uma possível influência do fator regional, uma vez que, no estado do Paraná, existem muitos descendentes de imigrantes poloneses, ucranianos, alemães, holandeses e italianos. A influência étnica é reforçada pelo fato de a estatura final do grupo A assemelhar-se à estatura final de pacientes com ST de outros países, como Estados Unidos, Itália, França, Áustria, Bélgica e Reino Unido (23,25,(31)(32)(33)(34).…”

“…Na análise de regressão múltipla, os principais fatores capazes de influenciar a estatura final das pacientes deste estudo foram o tipo de tratamento (GH + OX) e a estatura materna, semelhantemente ao descrito na literatura (9,16,19,21,33,35). Embora a idade cronoló-gica ao início do tratamento esteja correlacionada com uma maior estatura final (15,16,19,21,33,35), neste estudo não observamos essa correlação.…”

“…Embora a idade cronoló-gica ao início do tratamento esteja correlacionada com uma maior estatura final (15,16,19,21,33,35), neste estudo não observamos essa correlação.…”